Sunosi (solriamfetol) is a small molecule pharmaceutical. Solriamfetol was first approved as Sunosi on 2019-06-17. It is used to treat sleepiness in the USA. It has been approved in Europe to treat narcolepsy and obstructive sleep apnea. It is known to target sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. Sunosi's patents are valid until 2040-03-19 (FDA).
|Indication||narcolepsy, obstructive sleep apnea, sleepiness|
|Drug Class||Norepinephrineâ€“dopamine reuptake inhibitors|